Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) Overview
  3. Therapeutics Development
  4. Pipeline Products for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Overview
  5. Pipeline Products for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Comparative Analysis
  6. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Therapeutics under Development by Companies
  7. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Therapeutics under Investigation by Universities/Institutes
  8. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Companies
  13. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Investigation by Universities/Institutes
  14. Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Companies Involved in Therapeutics Development
  • Dicerna Pharmaceuticals, Inc.
  • Phylogica Limited
  • Sorrento Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/5h38t9/myc

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716